

Tuesday 13th June

8:00 – 9:00	Registration				
9:00 – 10:00	Andy Grieve <i>If you Can't Teach an Old Dog New Tricks, Can Old Dogs Teach Young Ones Old Tricks?</i>				
10:00 – 10:30	Break				
10:30 – 12:00	Advancing Quantitative Decision Making Methods (Decision Making SIG)	HTA & Launch & Life Cycle SIG: Connecting the dots: how can statisticians drive end-to-end thinking in the development of new medicines?	Innovations in Dose finding	Estimands	Cross Industry R collaborations and challenges (AIMS SIG)
	Kevin Kunzmann (Boehringer-Ingelheim) <i>Monitoring Probability of Success in Early Oncology Trials Using Multistate Models</i>	Rebecca Finch (Roche) Min-Hua Jen (Eli Lilly) Katrin Kupas (Bristol Myers Squibb)	Zhangyi He (Cancer Research UK) <i>MAP-Curvature: A Model-Free Approach for Analysing Dose-Finding Studies</i>	Camila Olarte Parra <i>Estimating Hypothetical Estimands with Causal Inference and Missing Data Estimators in a Diabetes Trial</i>	Martin Brown (PPD, AIMS SIG Chair) <i>AIMS SIG Update</i>
	Daniel Bratton (GSK) <i>Selection of Quantitative Decision-Making Criteria Using Weighted Decision Error Rates</i>	Anders Gorst-Rasmussen (Novo Nordisk) Amander Darekar (Pfizer) Jenny Devenport (Roche)	Anaïs Andrillon (Saryga) <i>Surv-CRM-12: A Bayesian Phase I/II Survival CRM for Right-Censored Toxicity Endpoints with Competing Disease Progression</i>	Karl Karu (IQVIA) <i>Time to Deterioration in Function/Symptom Endpoints Under the Estimand Framework: Considerations on Plausible Strategies and Associated Estimators</i>	Kevin Kunzmann (Boehringer-Ingelheim) & Daniel Leibovitz (Incyte) <i>Plugging the Gaps: Lessons Learned from Implementing the 'MMRM' (Mixed Models for Repeated Measures) R package</i>

	Marie-Karelle Riviere (Saryga) <i>Decision-making Frameworks Using Multiple Correlated Endpoints</i>		Daniel Slade (AstraZeneca) <i>Comparison of Statistical Methods using both Safety and Efficacy for Oncology Dose Escalation Studies</i>	Suzie Cro <i>Reference-Based Multiple Imputation for Longitudinal Binary Outcomes</i>	Lyn Taylor (PAREXEL) <i>Open-Source Collaboration for Comparing Analysis Method Implementations in Software (CAMIS)</i>
			Toby Batten (Veramed) <i>The New Normal for Dose Escalation Oncology Studies</i>		Christina Fillmore (GSK) <i>It is the Best of Times and the Worst of Times: A Summary of Working on R in Open-Source</i>
12:00 – 13:00	PSI Annual General Meeting				
13:00 – 14:00	Lunch				
14:00 – 15:30	Data Science SIG	Adaptive Designs	Building A Fantasy Stats Team - Unconscious Bias		PSI Biomarkers SIG: From Basics to Hot Topics!
	Julia Chernova (Bayer) <i>An Introduction to Digital Clinical Measures for Clinical Teams - a Statistician's Perspective</i>	Dr Ayon Mukherjee (IQVIA) <i>Covariate Adjusted Response Adaptive Designs for Semi-Parametric Survival Models</i>	Claire Brittain (UCB) Kim Hacquoil (Exploristics) Chetan Mistry (Veramed) Robert Donnelly		Deepak Parashar (University of Warwick) <i>Precision Medicine Trial Designs: Is There Hope?</i>
	Carsten Henneges (Sanofi) <i>Feature Selection and Hazard Rate Estimation</i>	Abigail Burdon (MRC Biostatistics Unit) <i>Adaptive Enrichment Trial Designs Using Joint Modelling of Longitudinal and Time-to-Event Data</i>			Nicole Krämer (Boehringer-Ingelheim) <i>Omics and Digital Biomarkers: Two Peas in a Pod or Two Worlds Colliding?</i>
	Vladimir Anisimov (Amgen)	Martin Kappler (Cytel) <i>Masked Goldilocks Approach for Selecting Final Sample Size</i>			Guillaume Desachy (AstraZeneca)

	<i>Modelling Restricted Patient Enrolment and Optimal Cost-Efficient Design in Clinical Trials</i>			<i>Who Said: A Collection of Biomarkers Datasets?</i>
	Domingo Salazar (AstraZeneca) <i>Weakly Supervision (Multiple Instance Learning)</i>	David Robertson (MRC Biostatistics Unit) <i>Point Estimation After Adaptive Designs: Practical Considerations and Guidance</i>		
15:30 – 16:00	Break			
16:00 – 17:30	Regulatory Hot Topics Session Florian Lasch <i>Estimands in non-inferiority trials</i> Shirley Hopper <i>MHRA perspective: Recent changes/initiatives in the Regulatory Landscape</i> Florian Klinglmüller <i>EMA Perspective: Recent changes/initiatives in the Regulatory Landscape</i>			
17:30 – 19:30	Break & Free Time			
19:30 – 20:00	Drinks Reception			
20:00 – 00:00	Gala Dinner <i>Kindly sponsored by Phastar</i>			